NYB.AI and Pnaseer Form Strategic Alliance to Advance AI-Powered Hair Regeneration Research
NYB.AI, a pioneer in AI-driven drug discovery, and Pnaseer Inc., a leader in bio-nanoparticle drug delivery technologies, have announced a strategic partnership to accelerate the discovery and development of novel compounds that stimulate hair follicle regeneration. The collaboration, centered around a new joint initiative known as Project Follica, merges cutting-edge artificial intelligence with next-generation delivery systems to push the boundaries of regenerative medicine.
The partnership was formalized through a signed agreement between Giang Nguyen, CEO of NYB.AI, and Dr. Shin Sung Min, Co-Founder and Global Business Development Director of Pnaseer Inc., signifying a deepened commitment to shared innovation in the fields of dermatology and hair biology.
Project Follica: A Data-Driven Approach to Hair Regeneration
At the core of this collaboration is Project Follica, a multi-phase initiative aimed at identifying, optimizing, and delivering both natural and synthetic compounds capable of promoting hair growth through hair follicle regeneration. The project brings together NYB.AI’s strength in AI-powered compound discovery with Pnaseer’s bio-nanoparticle platform for targeted drug delivery.
The project has three primary objectives:
- Build an AI-Informed Compound Database: The partnership will generate a comprehensive catalog of candidate compounds mapped to key biological pathways known to regulate hair follicle cycling and regeneration. This includes molecules that influence stem cell activation, immune modulation, and signaling networks like Wnt/β-catenin and BMP.
- Develop Formulation-Ready Prototypes: Promising compounds identified through AI modeling will be formulated using Pnaseer’s advanced delivery systems, optimized for topical or systemic application. These prototypes will be designed to meet preclinical standards for safety, bioavailability, and efficacy.
- Establish a Scalable Discovery Framework: The collaboration aims to create a repeatable, scalable AI discovery pipeline specifically designed for applications in dermatological therapeutics and regenerative medicine, with potential to expand beyond hair restoration.
AI-Powered Compound Discovery with NYB.AI
NYB.AI is contributing its proprietary AI technology, which excels in predicting compound-target interactions, identifying bioactivity profiles, and prioritizing high-potential molecules across vast chemical libraries. By leveraging machine learning, deep learning, and structural bioinformatics, NYB.AI’s platform can rapidly identify novel compounds that interact with biological targets involved in hair growth and follicle regeneration.
“Project Follica is more than just a compound screening initiative—it’s a reimagining of how the industry tackles regenerative challenges,” said Giang Nguyen, CEO of NYB.AI. “The combination of deep biological knowledge and artificial intelligence enables us to discover bioactive compounds that may have been missed by traditional screening methods.”
In addition to accelerating early-stage discovery, NYB.AI’s models will also support structure-activity relationship (SAR) optimization, guiding chemists and formulation scientists on how to enhance molecular efficacy while minimizing potential toxicity.
Precision Drug Delivery with Pnaseer’s Bio-Nanoparticle Platform
On the other end of the pipeline, Pnaseer brings its innovative bio-nanoparticle drug delivery platform, which is designed to improve compound stability, targeted delivery to follicular tissues, and controlled release profiles. These delivery systems are especially important in dermatological applications, where skin penetration and local tissue specificity are critical to therapeutic success.
“Hair regeneration requires a multidisciplinary approach that bridges biology, materials science, and computational modeling,” said Dr. Shin Sung Min, Global Business Development Director and Co-Founder of Pnaseer. “With NYB.AI’s AI-driven insights and our delivery innovation, we aim to unlock safer, more effective treatments that overcome the limitations of current solutions.”
Pnaseer will also lead the formulation development, incorporating identified compounds into stable prototypes optimized for skin absorption, follicle targeting, and minimal systemic exposure. This makes the platform ideally suited for both cosmetic and clinical applications.
A Collaborative Scientific Workflow
The partnership emphasizes collaborative research and resource sharing, with both companies contributing critical assets:
- Compound Libraries & Databases: NYB.AI will provide access to annotated libraries of natural and synthetic molecules, supported by predictive AI scoring.
- Biological Pathway Data: Pnaseer will contribute insights into signaling pathways, cellular models, and tissue-specific biomarkers involved in follicle regeneration.
- AI and Computational Tools: Advanced in silico models will be used to simulate compound efficacy, binding interactions, and toxicity before moving into lab-based testing.
- In Vitro & Preclinical Validation: Both companies will jointly conduct laboratory experiments to validate efficacy, optimize delivery mechanisms, and prepare for future clinical translation.
This end-to-end approach is designed to dramatically reduce the time and cost associated with traditional drug discovery and development pipelines.
Looking Ahead: Transforming the Hair Restoration Landscape
The global demand for effective and scientifically validated hair restoration treatments continues to grow, yet current options remain limited in efficacy, safety, and scientific rigor. Project Follica represents a new frontier—where AI-driven discovery meets advanced delivery science to address a condition that affects millions worldwide.
The outcomes of this partnership may not only result in a new generation of hair regeneration therapies, but also establish a blueprint for future AI-enabled breakthroughs in dermatology and regenerative medicine.
With this partnership, NYB.AI and Pnaseer are poised to transform how compounds for hair regeneration are discovered, formulated, and brought to market—turning scientific insights into real-world solutions for hair loss and beyond.
About Pnaseer Inc:
Pnaseer Inc. is a biotech firm focused on advanced drug delivery tech. It enhances approved drugs’ performance using its proprietary bio-nanoparticle platform. By enabling precise delivery of active compounds, Pnaseer’s tech supports various applications, from pharma manufacturing to wellness treatments, while PNAS Therapeutics handles clinical development and commercialization.
About NYB.AI
NYB.AI is a biotech company using AI and biological data to understand drug-target interactions in disease pathways. Through its AI platform and compound libraries, NYB.AI identifies promising therapeutic molecules and optimizes them for effectiveness. Using advanced machine learning techniques, NYB.AI accelerates the discovery of next-generation treatments for cancer and chronic diseases.
